Székely Hajnal, Hagymási Krisztina, Sápi Zoltán, Hartmann Erika, Mihály Emese, Muzes Györgyi, Tulassay Zsolt
Semmelweis Egyetem, Általános Orvostudományi Kar, II. Belgyógyászati Klinika, Budapest, Szentkirályi u. 46. 1088.
Orv Hetil. 2011 Nov 6;152(45):1818-26. doi: 10.1556/OH.2011.29234.
Retroperitoneal fibrosis is the chronic, nonspecific inflammation of the retroperitoneum. About 75% of the cases are idiopathic. The pathomechanism of the disorder is not clearly defined. Autoimmune inflammation and secondary fibrosis are the main suspected mechanisms against an unknown factor possibly related to atherosclerosis. Symptoms and laboratory parameters are nonspecific which make the diagnosis difficult. At the time of the diagnosis complications are often present. After the urological and surgical management of the complications, the aim of the medical treatment is immunosuppression. Corticosteroids are usually used for treatment, although the optimal dosage and the duration of the treatment are not known. After therapy cessation relapse may occur, requiring repeated steroid therapy or addition of steroid sparing drugs. Predicting factors for treatment response, corticosteroid demand or relapse are not known. Authors review the medical history of two patients with retroperitoneal fibrosis and discuss diagnostic difficulties of this disorder.
腹膜后纤维化是一种腹膜后的慢性非特异性炎症。约75%的病例为特发性。该疾病的发病机制尚未明确界定。自身免疫性炎症和继发性纤维化是针对可能与动脉粥样硬化相关的未知因素的主要疑似机制。症状和实验室指标均无特异性,这使得诊断困难。在诊断时,并发症往往已经存在。在对并发症进行泌尿外科和外科处理后,药物治疗的目的是免疫抑制。通常使用皮质类固醇进行治疗,尽管最佳剂量和治疗持续时间尚不清楚。停药后可能会复发,需要重复使用类固醇治疗或加用类固醇节省药物。目前尚不清楚治疗反应、皮质类固醇需求或复发的预测因素。作者回顾了两名腹膜后纤维化患者的病史,并讨论了该疾病的诊断难点。